References
1. OCREVUS® (ocrelizumab) Subcutaneous SmPC, Roche Registration GmbH, Germany; 2. Hauser SL, et al. The Patient Impact of 11 Years of Ocrelizumab Treatment in Multiple Sclerosis: Long-Term Data from the Phase III OPERA and ORATORIO Studies. Presented at ECTRIMS, 9–11 October 2024, Copenhagen, Denmark. P1664; 3. FDA, OCREVUS ZUONOVO - HIGHLIGHTS OF PRESCRIBING INFORMATION, 2025; 4. Hauser SL, et al. Poster presented at ECTRIMS 2024 (P1664); 5. OCREVUS SC Summary of Product Characteristics; 6. Bove R, et al. Oral presented at ECTRIMS 2024 (O039); 7. Vukusic S, et al. Poster presented at ECTRIMS 2024 (P591); 8. Yeh et al., NeurolNeuroimmunolNeuroinflamm 2024; 9. Data on File: OCREVUS Patient Exposure Nov 2025; 10. Hauser SL, et al. Presented at: ECTRIMS 2024 (P300); 11. Newsome et al. Poster presented at ACTRIMS 2026 (P125).
aDoes not include all aspects of the treatment. Actual injection time may vary. Oral premedications are recommended at least 30 minutes before each injection with 20 mg of dexamethasone (or an equivalent corticosteroid) and an antihistamine (eg, desloratadine). OCREVUS SC is HCP administered and is recommended that post-injection monitoring with access to appropriate medical support to manage severe injection reactions for at least 1 hour after the first injection and at least 15 minutes after subsequent injections.
b11-year annualised event rate of 0.038 with IFN-OCR vs 0.029 with OCR-OCR accounts for delay of 8.2 years until next event.
cOcrelizumab can be used during breastfeeding starting a few days after birth per SMPC.